{"id":"glucose-peritoneal-dialysis-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Peritonitis"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Electrolyte imbalances"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The solution contains glucose at varying concentrations (typically 1.5%, 2.5%, or 4.25%) that acts as an osmotic agent. When instilled into the peritoneal cavity, glucose draws fluid from the bloodstream across the peritoneal membrane into the dialysate, enabling removal of excess water and uremic toxins in patients with end-stage renal disease. The higher the glucose concentration, the greater the osmotic effect and ultrafiltration rate.","oneSentence":"Glucose peritoneal dialysis solution provides osmotic ultrafiltration during peritoneal dialysis by creating an osmotic gradient across the peritoneal membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:10.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"End-stage renal disease requiring peritoneal dialysis"},{"name":"Fluid removal and uremic toxin clearance in peritoneal dialysis patients"}]},"trialDetails":[{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":"End Stage Renal Disease","enrollment":170},{"nctId":"NCT06443021","phase":"NA","title":"Influence of Variable Inflow Volume, Dwell Duration and Glucose Concentration on Ultrafiltration Volume in APD Patients","status":"WITHDRAWN","sponsor":"Fresenius Medical Care Deutschland GmbH","startDate":"2025-10","conditions":"Renal Failure, Chronic Kidney Diseases","enrollment":""},{"nctId":"NCT07134595","phase":"NA","title":"Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings","status":"RECRUITING","sponsor":"National University Health System, Singapore","startDate":"2024-11-18","conditions":"Children on Chronic Peritoneal Dialysis","enrollment":44},{"nctId":"NCT07077538","phase":"NA","title":"Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients","status":"RECRUITING","sponsor":"The People's Hospital of Gaozhou","startDate":"2025-07-30","conditions":"Peritoneal Dialysis, Diabetes","enrollment":70},{"nctId":"NCT06358820","phase":"PHASE4","title":"Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution","status":"COMPLETED","sponsor":"The People's Hospital of Gaozhou","startDate":"2023-12-03","conditions":"Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution","enrollment":149},{"nctId":"NCT06492031","phase":"","title":"Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2024-06-28","conditions":"Chronic Renal Failure","enrollment":889},{"nctId":"NCT06597201","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.","status":"RECRUITING","sponsor":"Chengdu Qingshan Likang Pharmaceutical Co., Ltd","startDate":"2024-08-09","conditions":"End Stage Renal Disease (ESRD)","enrollment":400},{"nctId":"NCT06723223","phase":"NA","title":"Novel Combined Function Test for Patients on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Lund University","startDate":"2021-11-02","conditions":"End Stage Kidney Disease (ESRD)","enrollment":34},{"nctId":"NCT06552546","phase":"NA","title":"Pharmacokinetics of Single- and Double-dose Icodextrin","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-08-15","conditions":"Peritoneal Dialysis","enrollment":16},{"nctId":"NCT05721404","phase":"PHASE4","title":"Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-05-24","conditions":"Peritoneal Dialysis","enrollment":194},{"nctId":"NCT02755610","phase":"NA","title":"Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2016-05-02","conditions":"End-Stage Kidney Disease, Peritonitis","enrollment":880},{"nctId":"NCT05185999","phase":"PHASE1","title":"Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2022-10-17","conditions":"Chronic Kidney Failure","enrollment":10},{"nctId":"NCT06119373","phase":"NA","title":"Incremental PD With Single Icodextrin Exchange","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-12-01","conditions":"Peritoneal Dialysis Complication, Residual Kidney Function, Survival","enrollment":72},{"nctId":"NCT05195125","phase":"PHASE1","title":"Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2022-02-01","conditions":"End Stage Liver DIsease, Obesity, Acute Kidney Injury","enrollment":15},{"nctId":"NCT05780086","phase":"PHASE1","title":"Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution","status":"UNKNOWN","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2023-02-03","conditions":"Chronic Kidney Diseases","enrollment":10},{"nctId":"NCT04001036","phase":"PHASE2","title":"Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD","status":"TERMINATED","sponsor":"Iperboreal Pharma Srl","startDate":"2019-09-01","conditions":"End Stage Renal Disease","enrollment":11},{"nctId":"NCT04238338","phase":"","title":"Association of MLR With Risk of Death and Cardiovascular Events in PD Patients","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2020-06-01","conditions":"Peritoneal Dialysis, Inflammation","enrollment":266},{"nctId":"NCT05214872","phase":"","title":"The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2016-03-25","conditions":"Atherosclerosis of Artery, Inflammation, Chronic Kidney Diseases","enrollment":252},{"nctId":"NCT02042768","phase":"","title":"Observational Study of Glucose Metabolism and How Dialysate Glucose Affects This","status":"COMPLETED","sponsor":"Keele University","startDate":"2013-03","conditions":"Glucose Metabolism Disorders","enrollment":1451},{"nctId":"NCT03205553","phase":"PHASE1","title":"Direct Peritoneal Resuscitation in Gastroschisis","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2018-02-01","conditions":"Gastroschisis","enrollment":3},{"nctId":"NCT02694068","phase":"","title":"Biological Determinants of Peritoneal Dialysis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-15","conditions":"End-Stage Kidney Disease","enrollment":4865},{"nctId":"NCT01228279","phase":"PHASE4","title":"Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2007-07","conditions":"End-stage Renal Disease (ESRD), Kidney Disease","enrollment":50},{"nctId":"NCT04017572","phase":"NA","title":"Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study","status":"COMPLETED","sponsor":"Lund University","startDate":"2019-06-01","conditions":"End Stage Kidney Disease, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":21},{"nctId":"NCT02708407","phase":"NA","title":"PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease","status":"TERMINATED","sponsor":"University of Nottingham","startDate":"2016-01","conditions":"Heart Failure, Chronic Kidney Disease","enrollment":11},{"nctId":"NCT03801226","phase":"EARLY_PHASE1","title":"Zero Sodium Peritoneal Dialysate Protocol Pilot Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-12-01","conditions":"Potential Applications for Heart Failure, Volume Overload","enrollment":12},{"nctId":"NCT02212327","phase":"","title":"Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"End Stage Renal Disease","enrollment":41},{"nctId":"NCT00755456","phase":"PHASE2","title":"Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)","status":"COMPLETED","sponsor":"Iperboreal Pharma Srl","startDate":"2008-01","conditions":"End Stage Renal Disease, Insulin Resistance","enrollment":35},{"nctId":"NCT00858182","phase":"PHASE2","title":"Study of Safety and Efficacy on New Peritoneal Dialysis Solutions","status":"WITHDRAWN","sponsor":"Iperboreal Pharma Srl","startDate":"2009-05","conditions":"End-Stage Renal Disease","enrollment":""},{"nctId":"NCT00755404","phase":"PHASE2","title":"Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)","status":"WITHDRAWN","sponsor":"Iperboreal Pharma Srl","startDate":"2007-06","conditions":"End Stage Renal Disease, Diabetes","enrollment":""},{"nctId":"NCT00851838","phase":"PHASE2","title":"L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis","status":"COMPLETED","sponsor":"Iperboreal Pharma Srl","startDate":"2009-06","conditions":"End-Stage Renal Disease","enrollment":5},{"nctId":"NCT03190018","phase":"NA","title":"A Feasibility Study of Peritoneal Dialysis With CLS PD, Which Removes Toxins and Maintains a Stable Ultrafiltration by Continuously Regenerating a Recirculating Intraperitoneal Fluid, in Patients With End Stage Renal Disease, ESRD, With PD Therapy.","status":"COMPLETED","sponsor":"Triomed AB","startDate":"2017-06-01","conditions":"Peritoneal Dialysis","enrollment":5},{"nctId":"NCT01242904","phase":"PHASE2","title":"Use of a Bimodal Solution for Peritoneal Dialysis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-09-30","conditions":"End Stage Renal Disease","enrollment":36},{"nctId":"NCT02772146","phase":"NA","title":"A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure","status":"TERMINATED","sponsor":"Triomed AB","startDate":"2016-05-11","conditions":"Heart Failure, Cardio-Renal Syndrome","enrollment":2},{"nctId":"NCT01659554","phase":"PHASE2","title":"A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-03","conditions":"Recurrent Ovarian Cancer, Fallopian Tube Cancer","enrollment":4},{"nctId":"NCT01119196","phase":"NA","title":"The Measurement of Insulin Resistance in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"End Stage Renal Disease","enrollment":10},{"nctId":"NCT01044446","phase":"PHASE4","title":"Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-01","conditions":"Peritonitis","enrollment":56},{"nctId":"NCT01753154","phase":"PHASE4","title":"The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis","status":"COMPLETED","sponsor":"Fresenius Medical Care Deutschland GmbH","startDate":"2011-07","conditions":"Chronic Renal Failure","enrollment":25},{"nctId":"NCT01170858","phase":"NA","title":"Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-08","conditions":"End Stage Renal Disease","enrollment":100},{"nctId":"NCT01353638","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis","status":"TERMINATED","sponsor":"Christoph Aufricht","startDate":"2011-04","conditions":"End Stage Renal Disease","enrollment":25},{"nctId":"NCT00776191","phase":"PHASE4","title":"Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2008-09","conditions":"Endstage Renal Disease","enrollment":5},{"nctId":"NCT01021878","phase":"PHASE4","title":"Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Pontifícia Universidade Católica do Paraná","startDate":"2009-10","conditions":"Disorders Associated With Peritoneal Dialysis","enrollment":60},{"nctId":"NCT00966615","phase":"PHASE4","title":"The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-09","conditions":"Renal Failure, ESRD, Cardiovascular Disease","enrollment":68},{"nctId":"NCT01632046","phase":"PHASE4","title":"Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2004-03","conditions":"Chronic Renal Failure, Peritoneal Membrane Disorder","enrollment":42},{"nctId":"NCT01315314","phase":"PHASE4","title":"Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2005-10","conditions":"Kidney Failure, Chronic, Disorders Associated With Peritoneal Dialysis","enrollment":146},{"nctId":"NCT00922701","phase":"PHASE2","title":"L-Carnitine in Peritoneal Dialysis","status":"COMPLETED","sponsor":"Iperboreal Pharma Srl","startDate":"2004-06","conditions":"End-Stage Renal Disease","enrollment":4},{"nctId":"NCT00725517","phase":"PHASE4","title":"Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2005-12","conditions":"Chronic Kidney Disease, Peritoneal Dialysis","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DEATH"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"glucose peritoneal dialysis solution","genericName":"glucose peritoneal dialysis solution","companyName":"Chengdu Qingshan Likang Pharmaceutical Co., Ltd","companyId":"chengdu-qingshan-likang-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucose peritoneal dialysis solution provides osmotic ultrafiltration during peritoneal dialysis by creating an osmotic gradient across the peritoneal membrane. Used for End-stage renal disease requiring peritoneal dialysis, Fluid removal and uremic toxin clearance in peritoneal dialysis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}